Previous Close | 4.0900 |
Open | 4.1100 |
Bid | 4.3800 x 1400 |
Ask | 4.3500 x 3200 |
Day's Range | 4.1100 - 4.4000 |
52 Week Range | 1.6800 - 5.1250 |
Volume | |
Avg. Volume | 6,667,322 |
Market Cap | 1.014B |
Beta (5Y Monthly) | 1.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0600 |
Earnings Date | Oct 31, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.31 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARDX
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on November 20, 2023, the compensation committee of the company’s board of directors granted fourteen new non-executive employees options to purchase an aggregate of 221,805 shares of the company’s common stock, and granted sixte
In the ever-evolving investment landscape, penny stocks to buy emerge as the thrill-seekers’ darlings. Known for their high-risk, high-reward nature, these stocks attract investors with their low share prices and the promise of substantial gains. Furthermore, these stocks mirror current growth trends in various industries, demonstrating resilience in a tumultuous economy. Among them, certain standouts are well-positioned to evolve amidst rising interest rates. The appeal of these stocks extends
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Ardelyx management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in New York City. To access the live webcast of Ardelyx's session, p